CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
587.39MUSDvs all stocks (USD)
Revenue (TTM)
54.09MUSDvs all stocks (USD)
Profit Margin
-144.63%Beta
1.47xvs all stocks
52-Week Change
-17.17%vs all stocks
Market Capitalization
587.39MUSDvs all stocks (USD)
Enterprise Value
547.94MUSDvs all stocks (USD)
Forward P/E
-8.21xPrice to Sales (TTM)
10.86xEnterprise to Revenue
10.13xEnterprise to EBITDA
-10.50xGross Margin
70.93%Profit Margin
-144.63%Operating Margin
-59.51%Return on Assets (TTM)
-29.20%Revenue (TTM)
54.09MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4500USDUpdated Sep 26, 2026Quarterly Revenue Growth
38.10%Gross Profit (TTM)
36.26MUSDvs all stocks (USD)
EBITDA (TTM)
-52.20MUSDvs all stocks (USD)
Net Income (TTM)
-78.23MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
38.15%Operating Cash Flow (TTM)
-45.37MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-26.89MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
44.55MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
18.55MUSDFY2025 · Dec 31, 2025Gross Profit
25.99MUSDFY2025 · Dec 31, 2025Operating Income
-71.05MUSDvs all stocks (USD)
Pre-tax Income
-83.78MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-83.78MUSDFY2025 · Dec 31, 2025EBIT
-66.68MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-66.14MUSDFY2025 · Dec 31, 2025Research & Development
17.19MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
79.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.37MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
17.10MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.7800USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.7800USDFY2025 · Dec 31, 2025Basic Shares Outstanding
106.93MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
106.93MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-83.78MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-56.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
121.17MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
6.10MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-83.78MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
548.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.62MUSDFY2025 · Dec 31, 2025Other Non-cash Items
11.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.37MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
19.52MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-697.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-26.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-821.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
99.81MUSDFY2025 · Dec 31, 2025Shares Outstanding
125.51MSharesUpdated Sep 26, 2026Float Shares
114.61MSharesUpdated Sep 26, 2026Shares Short
27.16MSharesUpdated Sep 26, 2026Short Ratio
9.05daysvs all stocks
Short % of Shares Outstanding
22.65%vs all stocks
% Held by Insiders
2.90%vs all stocks
% Held by Institutions
58.39%vs all stocks
Total Cash (MRQ)
98.49MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7850USDUpdated Sep 26, 2026Total Debt (MRQ)
59.03MUSDvs all stocks (USD)
Current Ratio (MRQ)
7.19xBook Value per Share (MRQ)
-0.4510USDUpdated Sep 26, 2026Total Assets
160.43MUSDvs all stocks (USD)
Total Current Assets
149.27MUSDFY2025 · Dec 31, 2025Total Liabilities
194.09MUSDFY2025 · Dec 31, 2025Total Non-current Assets
11.16MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
146.48MUSDFY2025 · Dec 31, 2025Total Current Liabilities
47.61MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
121.17MUSDFY2025 · Dec 31, 2025Accounts Receivable
8.01MUSDFY2025 · Dec 31, 2025Inventory
6.17MUSDFY2025 · Dec 31, 2025Accounts Payable
29.86MUSDFY2025 · Dec 31, 2025Short-term Debt
10.63MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.09MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.00MUSDFY2025 · Dec 31, 2025Long-term Debt
31.86MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
33.21MUSDFY2025 · Dec 31, 2025Common Stock (Book)
122.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-447.00MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-33.66MUSDvs all stocks (USD)
52-Week Low
2.93USDUpdated Sep 26, 202652-Week High
7.55USDUpdated Sep 26, 202652-Week Change
-17.17%vs all stocks
Beta
1.47xvs all stocks
50-Day MA
4.49USDUpdated Sep 26, 2026200-Day MA
4.38USDUpdated Sep 26, 2026Avg 10-Day Volume
2.33MSharesUpdated Sep 26, 2026Avg 30-Day Volume
2.88MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-0.6600USDUpdated Sep 26, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.71Profit Margin: -1.45
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
OrthoPediatrics Corp.
Tier 1ProductionApproval-Gated PipelineRule
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SS Innovations International, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gkht Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Yatai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Surrozen, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
JFrog Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Fastly Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC